Abstract 936P
Background
There are over 500,000 survivors of head and neck cancer (HNC) in the United States. While chronic pain is a common symptom across all cancer sites, we hypothesized it is more prevalent in HNC compared with other cancer sites, due to tumor location, treatment modality and functional impairment associated with HNC.
Methods
To compare self-reported chronic pain prevalence, we built a retrospective cohort of adult survivors with a history of cancer, using the National Health Interview Survey (NHIS) from 2010 to 2021. Study participants were grouped into HNC (n = 354) vs. other cancer survivors (n = 24,055), based on self-report of a previous cancer diagnosis. We estimated weighted prevalence rates of chronic pain in our sample, and in the final models, we estimated odds of reporting chronic pain while adjusting for sociodemographic (race, insurance, education, income, employment and smoking history) and clinical (depression, and self-rated health status) factors, using multivariate logistic regression analysis.
Results
Weighted, age-adjusted prevalence of chronic pain was significantly higher in HNC compared to other cancers (HNC = 45.5%, 95% CI: 42.6%, 48.5% vs. other cancers = 31.6%, 95% CI: 29.9%, 33.2%; p = 0.02). After adjusting for clinical and sociodemographic covariates, odds of reporting chronic pain remained significantly higher among HNC survivors compared to other cancers (aOR=1.34, 95% CI: 1.03, 1.75). Other factors associated with self-reported chronic pain included having depression (aOR=2.03, 95% CI: 1.90, 2.17), ≥ 65 years (aOR=0.74, 95% CI: 0.68, 0.80), being Hispanic (aOR=0.70, 95% CI:0.59, 0.83) compared to a non-Hispanic White, having private insurance (aOR=0.74, 95% CI: 0.69, 0.80), and education below high school level (aOR=1.39, 95% CI: 1.24, 1.56).
Conclusions
Chronic pain is highly prevalent among survivors of HNC, with almost 50% reporting chronic pain. Additionally, survivors of HNC are 34 percent more likely to report chronic pain compared to non-HNC survivors. Our findings highlight the burden of chronic pain in cancer, and the pressing need for effective pain management especially in HNC survivors.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
927P - Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancers
Presenter: Laia Alemany
Session: Poster session 03
928P - Radiomic analysis based on machine learning of multi-MR sequences to assess early treatment response in locally advanced nasopharyngeal carcinoma
Presenter: Lei Qiu
Session: Poster session 03
929P - Advanced laryngeal squamous cell carcinoma prognosis and machine learning insights
Presenter: Tala Alshwayyat
Session: Poster session 03
Resources:
Abstract
930P - Real-world data analysis of oncological outcomes in patients with pathological extranodal extension (ENE) in OSCC: A proposal to refine the pathological nodal staging system
Presenter: Abhinav Thaduri
Session: Poster session 03
931P - Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma
Presenter: Kexin Shi
Session: Poster session 03
932P - Accuracy and prognostic implications of extranodal extension on radiologic imaging in HPV-positive oropharyngeal cancer (HNCIG-ENE): A multinational, real-world study
Presenter: Hisham Mehanna
Session: Poster session 03
933P - Prediction of survival in patients with head and neck merkel cell carcinoma: Statistical and machine-learning approaches
Presenter: Jehad Yasin
Session: Poster session 03
934P - Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study
Presenter: Hisham Mehanna
Session: Poster session 03
937P - Pain, fatigue and depression symptom cluster in head and neck cancer survivors
Presenter: Iakov Bolnykh
Session: Poster session 03